Vapotherm
The only mask-free respiratory support tool- an alternative to NiPPV for treating undifferentiated respiratory distress.
The only mask-free respiratory support tool- an alternative to NiPPV for treating undifferentiated respiratory distress.
Vapotherm, Inc. is a biotechnology, health care, and manufacturing company founded in 1999, headquartered in the United States. It has pioneered the high flow nasal cannula and its advanced form, Vapotherm high velocity therapy, revolutionizing respiratory support. The Precision Flow® system offers clinicians a reliable tool for multiple patient populations, delivering not only oxygenation but also mask-free respiratory support with the comfort of heated humidified high flow. The company's recent success is evident as it became publicly traded, with its common stock trading on the OTCQX tier of the OTC Markets under the symbol “VAPO”. Vapotherm, Inc. secured a considerable $23.00M Post-IPO Equity investment on 08 February 2023. This latest investment showcases investor confidence in the company's innovative approach to respiratory distress treatment and its potential for further growth and impact.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $23.00M | - | 08 Feb 2023 | |
| Post-IPO Debt | $52.00M | 1 |
|
26 Oct 2020 |
| Series D | $10.00M | 5 |
|
01 Sep 2018 |
| Series D | $45.00M | 5 |
|
25 May 2017 |
| Series C | $30.00M | 6 |
|
24 Nov 2015 |
No recent news or press coverage available for Vapotherm.
We care about your data, and we'd love to use cookies make your experience better.
